Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment satisfaction and symptoms during opioid maintenance therapy optimization
2015-002440-13Phase 4Terminated
- Sponsor
- Medical University of Innsbruck
- Start
- Nov 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of methadone, levomethadone, buprenorphine, buprenorphine + naloxone, morphine and 1 more in opioid use disorder (OUD), sponsored by Medical University of Innsbruck. Primary endpoints: Treatment satisfaction and its influence on compliance and outcome and Systematic collection of treatment-related data during routine opioid maintenance therapy. Started Nov 2015; status: terminated.
02
Drugs
methadonelevomethadonebuprenorphinebuprenorphine + naloxonemorphine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on 2015-002440-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002440-13.